News in the World (UK), 26 Mar. 2018 13:09:06The first vaccine is due to be administered next month in the UK, and the first clinical trial will start in mid-March.
The National Vaccine Advisory Committee (NVAC) said it had agreed to a five-year contract to deliver the vaccine, but that its main priority would be to assess whether it was safe.
“The key to delivering a vaccine to the NHS is to ensure that the vaccine is safe,” said Peter Wardle, the NVAC chairman.
“If the vaccine was safe, it wouldn’t be required for routine use.”
The vaccine is designed to stop the spread of the coronaviruses coronaviral disease, coronavillosis and influenza.
It is manufactured by Pfizer in the US and is expected to be given to patients aged 65 and over.
The company said the vaccine had been tested and approved by regulators in the United States, Canada, France, Australia and New Zealand.
The new vaccine, which is also being tested in the Netherlands, is designed for people aged 65 or over and is available as an injection, nasal spray or in pill form.
The first trial in the U.K. will begin next month.
In the Netherlands The vaccine will be administered in the first phase of a trial, with the aim of assessing whether it is safe and effective for people older than 65, and in the second phase of the trial, the company said.
“The vaccine will not be ready for use until the second half of 2019, at which point it will be fully distributed to patients and their healthcare team,” Pfizer said.
It added that in the third phase of its trial, which will start later in 2019, it planned to introduce the vaccine in the “middle of next year”.
The company’s vaccine will cost about $1,400 per dose, but the NHS will be reimbursed for all costs.
The U.S. National Institutes of Health, the U of A and the University of Pittsburgh are also in the running to make the vaccine.
Nasal spray will be delivered in pill and injection form, and oral sprays, but only in patients who have already been vaccinated.
The first phase will be a clinical trial, and will run for five years, starting in 2019.
Phase one, which involves taking the vaccine on average once every three months, will be completed in 2021, and phase two, which starts in 2021 and runs until 2023, will start the following year.
A trial in Sweden will begin in 2021.
For more stories like this, like The Conversation on Facebook or follow us on Twitter.